Soligenix Receives Hong Kong Patent for Therapeutic Use of Synthetic Hypericin to Treat Cutaneous T-Cell Lymphoma
---------------------------
Soligenix (NASDAQ:SNGX)'s stock had its "hold" rating reissued by analysts at B. Riley in a research note issued to investors on Thursday, AnalystRatings.com reports. They presently have a $2.00 price objective on the biopharmaceutical company's stock. B. Riley's price target indicates a potential upside of 33.33% from the stock's previous close.
Separately, Alliance Global Partners cut their price target on shares of Soligenix from $7.25 to $5.75 and set a "buy" rating on the stock in a report on Wednesday, December 23rd.
NASDAQ SNGX opened at $1.50 on Thursday. The company's 50-day moving average price is $1.71 and its 200-day moving average price is $1.91. The company has a current ratio of 2.30, a quick ratio of 2.30 and a debt-to-equity ratio of 0.02. The stock has a market cap of $47.23 million, a PE ratio of -2.42 and a beta of 1.42. Soligenix has a 12 month low of $1.21 and a 12 month high of $3.54.
Soligenix (NASDAQ:SNGX) last posted its quarterly earnings results on Thursday, November 12th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the Zacks' consensus estimate of ($0.11) by $0.05. The firm had revenue of $0.61 million for the quarter, compared to analysts' expectations of $1.10 million. Soligenix had a negative net margin of 567.04% and a negative return on equity of 328.25%. As a group, sell-side analysts forecast that Soligenix will post -0.54 earnings per share for the current year.
Large investors have recently added to or reduced their stakes in the stock. Wedbush Securities Inc. lifted its stake in Soligenix by 51.3% in the third quarter. Wedbush Securities Inc. now owns 25,200 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 8,548 shares during the period. Goldman Sachs Group Inc. lifted its stake in Soligenix by 54.2% in the second quarter. Goldman Sachs Group Inc. now owns 33,251 shares of the biopharmaceutical company's stock worth $70,000 after acquiring an additional 11,686 shares during the period. Squarepoint Ops LLC purchased a new stake in Soligenix in the third quarter worth about $129,000. FNY Investment Advisers LLC purchased a new stake in Soligenix in the third quarter worth about $160,000. Finally, GSA Capital Partners LLP lifted its stake in Soligenix by 1,086.1% in the third quarter. GSA Capital Partners LLP now owns 135,782 shares of the biopharmaceutical company's stock worth $243,000 after acquiring an additional 124,334 shares during the period. 9.39% of the stock is owned by institutional investors.
-----------------------------------
TP01 = 2,13000
TP02 = 2,87000
TP03 = 3,61000
TP04 = 4,35000
-------------------
---------------------------
Soligenix (NASDAQ:SNGX)'s stock had its "hold" rating reissued by analysts at B. Riley in a research note issued to investors on Thursday, AnalystRatings.com reports. They presently have a $2.00 price objective on the biopharmaceutical company's stock. B. Riley's price target indicates a potential upside of 33.33% from the stock's previous close.
Separately, Alliance Global Partners cut their price target on shares of Soligenix from $7.25 to $5.75 and set a "buy" rating on the stock in a report on Wednesday, December 23rd.
NASDAQ SNGX opened at $1.50 on Thursday. The company's 50-day moving average price is $1.71 and its 200-day moving average price is $1.91. The company has a current ratio of 2.30, a quick ratio of 2.30 and a debt-to-equity ratio of 0.02. The stock has a market cap of $47.23 million, a PE ratio of -2.42 and a beta of 1.42. Soligenix has a 12 month low of $1.21 and a 12 month high of $3.54.
Soligenix (NASDAQ:SNGX) last posted its quarterly earnings results on Thursday, November 12th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the Zacks' consensus estimate of ($0.11) by $0.05. The firm had revenue of $0.61 million for the quarter, compared to analysts' expectations of $1.10 million. Soligenix had a negative net margin of 567.04% and a negative return on equity of 328.25%. As a group, sell-side analysts forecast that Soligenix will post -0.54 earnings per share for the current year.
Large investors have recently added to or reduced their stakes in the stock. Wedbush Securities Inc. lifted its stake in Soligenix by 51.3% in the third quarter. Wedbush Securities Inc. now owns 25,200 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 8,548 shares during the period. Goldman Sachs Group Inc. lifted its stake in Soligenix by 54.2% in the second quarter. Goldman Sachs Group Inc. now owns 33,251 shares of the biopharmaceutical company's stock worth $70,000 after acquiring an additional 11,686 shares during the period. Squarepoint Ops LLC purchased a new stake in Soligenix in the third quarter worth about $129,000. FNY Investment Advisers LLC purchased a new stake in Soligenix in the third quarter worth about $160,000. Finally, GSA Capital Partners LLP lifted its stake in Soligenix by 1,086.1% in the third quarter. GSA Capital Partners LLP now owns 135,782 shares of the biopharmaceutical company's stock worth $243,000 after acquiring an additional 124,334 shares during the period. 9.39% of the stock is owned by institutional investors.
-----------------------------------
TP01 = 2,13000
TP02 = 2,87000
TP03 = 3,61000
TP04 = 4,35000
-------------------